molecules of the month


systemic, oral DGAT2 inhibitor

Ph. II for NASH with fibrosis

opt. of liver-targeting candidate PF-06427878

J. Med. Chem., 02 November 2022

Pfizer, Cambridge, MA and Groton, CT

ervogastat chemical structure systemic, oral DGAT2 inhibitor- Pfizer, Cambridge, MA and Groton, CT
4 mins read

Toward a first-in-class DGAT2 inhibitor for the treatment of NASH. Hepatic triglyceride (TG) accumulation is a symptom of non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH), which is characterized by hepatocyte damage, inflammation and collagen deposits (fibrosis). NASH has been estimated to impact 3-5% of the global population, with up to 29% of these individuals developing cirrhosis within 10 years and 4−27% of these patients developing hepatocellular carcinoma. Despite significant research, there are currently no FDA-approved medications for this burgeoning global health crisis. Several targets and mechanisms to treat NASH are being evaluated, including diacylglycerol acyltransferase (DGAT) inhibition. DGAT2 as a target. DGAT enzymes catalyze the esterification of diacylglycerol (DAG) in the final step of triglycerol…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: